Shilpa Medicare Limited reported a 96% rise in consolidated net profit to ₹2,433 crore for the financial year ended March 31, 2026, compared to ₹783 crore in the previous year. The company’s revenue from operations for the year increased to ₹15,389 crore from ₹12,864 crore in FY25. The Board of Directors approved the audited standalone and consolidated financial results for the year and recommended a final dividend of Re 0.60 per equity share of face value Re 1 each, subject to shareholder approval.

The standalone net profit for FY26 stood at ₹1,330 crore, a significant increase from ₹679 crore in the previous year. Revenue from operations in the standalone entity grew to ₹5,970 crore from ₹4,774 crore. The statutory auditors, M/s B N P S and Associates LLP, issued an unmodified opinion on the financial statements. The company also recorded exceptional items during the year, including a gain on the sale of a stake in Sravathi Advance Process Technologies Pvt Ltd and provisions for legal settlements.

Strategic Investments and Approvals

The Board approved an equity investment of 28% in Neo Green Power Project Private Limited by the company’s wholly owned subsidiaries—Shilpa Pharma Lifesciences Limited, Shilpa Biologicals Pvt Ltd, and Shilpa Biocare Pvt Ltd. The total group contribution for this investment is ₹4.44 crore, with the acquisition expected to be completed on or before June 15, 2026. This move is intended to meet the energy requirements for captive power consumption in the subsidiaries.

Furthermore, the Board appointed M/s. V.J. Talati & Co. as Cost Auditors and M/s ANEJA ASSOCIATES as Internal Auditors for FY 2026-27. The company also initiated the process to shift its registered office from Karnataka to Maharashtra, subject to member approval via postal ballot. Mr. Santosh Kumar Gunemoni was appointed as the scrutinizer for the postal ballot process.

Financial Performance Overview

The following table summarizes the key financial metrics for the standalone entity for the year ended March 31, 2026:

For the consolidated entity, profit after tax attributable to owners of the parent company rose to ₹2,433 crore in FY26 from ₹783 crore in the previous year. The company’s cash and cash equivalents improved to ₹4,518 crore as of March 31, 2026, compared to ₹2,857 crore in the prior year. The financial results were prepared in compliance with Indian Accounting Standards (Ind AS) and reviewed by the Audit Committee.

Shilpa Biologicals, a material subsidiary of Shilpa Medicare , has settled a commercial dispute with Sartorius Stedim India for Rs 9 Cr. The settlement agreement was executed on June 23, 2026, before the Hon'ble XI Addl. City Civil and Sessions Court, Commercial Court, Bengaluru, concluding legal proceedings in Commercial O.S. No. 153/2024.

Sartorius Stedim India had initially alleged a claim of Rs 20.13 Cr plus applicable interest. Following negotiations, the parties agreed to a reduced settlement amount of Rs 9 Cr, which was paid by Shilpa Biologicals. The company stated that the financial impact of this settlement is limited to the payment amount.

Details of the Settlement

The following table outlines the key particulars of the settlement and the judicial proceedings:

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.